Gynecologic Cancer
ZN-c3-005 - Zentalis
Official Title: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN‑c3 (Azenosertib) in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Study Purpose: To evaluate the safety, clinical activity, and pharmacokinetics of ZN-c3 (also known as azenosertib) in subjects with platinum-resistant, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer
Status:
Suspended